CVS Health Corp (IT:1CVS)
MILAN:1CVS
Holding IT:1CVS?
Track your performance easily

CVS Health (1CVS) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1CVS Analyst Ratings

Moderate Buy
14Ratings
8 Buy
6 Hold
0 Sell
Based on 14 analysts giving stock ratings to
CVS
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1CVS Stock 12 Month Forecast

Average Price Target

€61.76
▲(4.27% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for CVS Health in the last 3 months. The average price target is €61.76 with a high forecast of €77.39 and a low forecast of €54.63. The average price target represents a 4.27% change from the last price of €59.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"49":"€49","78":"€78","56.25":"€56.3","63.5":"€63.5","70.75":"€70.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77.38995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€77.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.7571801,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€61.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.6282,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€54.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[49,56.25,63.5,70.75,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jul<br/>2024","12":"Oct<br/>2024","25":"Oct<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.21,60.608457692307695,62.00691538461538,63.40537307692308,64.80383076923077,66.20228846153846,67.60074615384616,68.99920384615385,70.39766153846153,71.79611923076924,73.19457692307692,74.59303461538461,75.99149230769231,{"y":77.38995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.21,59.40593693076923,59.601873861538465,59.79781079230769,59.99374772307692,60.18968465384616,60.385621584615386,60.581558515384614,60.77749544615384,60.97343237692308,61.16936930769231,61.365306238461535,61.56124316923077,{"y":61.7571801,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.21,58.85755384615385,58.505107692307696,58.15266153846154,57.800215384615385,57.44776923076923,57.09532307692308,56.74287692307692,56.39043076923077,56.037984615384616,55.685538461538464,55.333092307692304,54.98064615384615,{"y":54.6282,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.747,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.801,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.987,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.478,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.952,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.756,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.373,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.869,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.1,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.482,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.46,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.67,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.21,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€77.39Average Price Target€61.76Lowest Price Target€54.63
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial
Buy
Reiterated
08/12/24
Truist Financial Sticks to Their Buy Rating for CVS Health (CVS)
Oppenheimer
Hold
Reiterated
08/09/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVS Health (NYSE: CVS), Insulet (NASDAQ: PODD) and Artivion (NYSE: AORT)
Cantor Fitzgerald
€52.81€56.45
Hold
-4.70%
Downside
Reiterated
08/07/24
Cantor Fitzgerald Remains a Hold on CVS Health (CVS)
Jefferies
€62.82
Buy
6.07%
Upside
Reiterated
08/07/24
CVS Health: A Buy Rating with Upside Potential Amidst Revised Earnings Guidance and Strong Operational Performance
Robert W. Baird
€55.54
Hold
-6.23%
Downside
Reiterated
06/26/24
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), CVS Health (NYSE: CVS) and Tempest Therapeutics (NASDAQ: TPST)

Best Analysts Covering CVS Health

Which Analyst Should I Follow If I Want to Buy IT:1CVS and Sell After:
1 Month
xxx
Success Rate
19/28 ratings generated profit
68%
Average Return
+1.51%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 67.86% of your transactions generating a profit, with an average return of +1.51% per trade.
3 Months
xxx
Success Rate
25/41 ratings generated profit
61%
Average Return
+0.85%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.98% of your transactions generating a profit, with an average return of +0.85% per trade.
1 Year
John RansomRaymond James
Success Rate
15/28 ratings generated profit
54%
Average Return
+4.65%
reiterated a buy rating 5 months ago
Copying John Ransom's trades and holding each position for 1 Year would result in 53.57% of your transactions generating a profit, with an average return of +4.65% per trade.
2 Years
xxx
Success Rate
15/28 ratings generated profit
54%
Average Return
+10.13%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.57% of your transactions generating a profit, with an average return of +10.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1CVS Analyst Recommendation Trends

Rating
Jun 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
1
1
0
0
0
Buy
19
14
10
10
13
Hold
19
22
19
16
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
37
29
26
27
In the current month, 1CVS has received 13 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 1CVS average Analyst price target in the past 3 months is €61.76.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

1CVS Financial Forecast

1CVS Earnings Forecast

Next quarter’s earnings estimate for 1CVS is €1.55 with a range of €1.38 to €1.67. The previous quarter’s EPS was €1.67. 1CVS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.56% of the time in the same period. In the last calendar year 1CVS has Outperformed its overall industry.
Next quarter’s earnings estimate for 1CVS is €1.55 with a range of €1.38 to €1.67. The previous quarter’s EPS was €1.67. 1CVS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.56% of the time in the same period. In the last calendar year 1CVS has Outperformed its overall industry.

1CVS Sales Forecast

Next quarter’s sales forecast for 1CVS is €84.24B with a range of €82.17B to €85.47B. The previous quarter’s sales results were €83.15B. 1CVS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 64.71% of the time in the same period. In the last calendar year 1CVS has Underperformed its overall industry.
Next quarter’s sales forecast for 1CVS is €84.24B with a range of €82.17B to €85.47B. The previous quarter’s sales results were €83.15B. 1CVS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 64.71% of the time in the same period. In the last calendar year 1CVS has Underperformed its overall industry.

1CVS Stock Forecast FAQ

What is IT:1CVS’s average 12-month price target, according to analysts?
Based on analyst ratings, CVS Health Corp’s 12-month average price target is €61.76.
    What is IT:1CVS’s upside potential, based on the analysts’ average price target?
    CVS Health Corp has 4.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CVS Health Corp a Buy, Sell or Hold?
          CVS Health Corp has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.
            What is CVS Health Corp’s share price target?
            The average share price target for CVS Health Corp is €61.76. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €77.39 ,and the lowest forecast is €54.63. The average share price target represents 4.27% Increase from the current price of €59.23.
              What do analysts say about CVS Health Corp?
              CVS Health Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of CVS Health Corp?
                To buy shares of IT:1CVS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis